Silverberg, JI; Gold, LS; Thaci, D; Pink, A; Papp, K; Legat, FJ; Cheong, SY; Ryzhkova, A; Ulianov, L; Piketty, C.
Continuous response with nemolizumab up to 56 weeks during a long-term extension study in patients with moderate-to-severe atopic dermatitis and partial or delayed skin response at Week 16 e Post-hoc analyses from the pooled ARCADIA 1&2 trials and long-te
J AM ACAD DERMATOL. 2025; 93(3): AB157-AB157.
Web of Science